Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Chicago, Illinois

This page shows live ClinicalTrials.gov search results for Chicago, Illinois, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
17832
Shown on this page
12
Current sort
Recently updated
Location scope
Chicago, IL
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Chicago, Illinois. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 397–408 of 17,832 matching trials in Chicago, IL.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in Chicago

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Active, not recruiting Phase 3 Interventional

A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

NCT05608291
View directory record Official record
Conditions
Melanoma
Interventions
Fianlimab, Cemiplimab, Pembrolizumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
1,564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
28
States / cities
La Jolla, California • San Francisco, California • Santa Monica, California + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 15, 2026, 4:00 AM EST
Recruiting Not applicable Interventional

BRIDGE Trial: Embedding Consumer-grade mHealth Technologies Into Cardiac Rehabilitation

NCT07741396
View directory record Official record
Conditions
Acute Myocardial Infarction (AMI), Percutaneous Coronary Intervention (PCI), Coronary Artery Bypass Graft Surgery (CABG), Chronic Heart Failure With Reduced Ejection Fraction (HFrEF), Heart Valve Repair or Replacement, Stable Angina Pectoris
Interventions
CBCR, BRIDGE mHealth intervention
Other · Behavioral
Lead sponsor
University of Illinois Chicago
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 15, 2026, 4:00 AM EST
Recruiting Phase 3 Interventional

A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed

NCT07650916
View directory record Official record
Conditions
HIV
Interventions
CAB ULA, RPV ULA, CAB LA, RPV LA
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
12 Years and older
Enrollment
564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
43
States / cities
Phoenix, Arizona • Bakersfield, California • Los Angeles, California + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 15, 2026, 4:00 AM EST
Active, not recruiting Phase 2Phase 3 Interventional

LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis

NCT02205762
View directory record Official record
Conditions
Langerhans Cell Histiocytosis
Interventions
Prednisone, Vinblastine, mercaptopurine, INDOMETHACIN, Methotrexate, Cytosine Arabinoside, 2-chlorodeoxyadenosine, hematopoietic stem cell transplantation (RIC-HSCT), Intravenous immunoglobulin
Drug · Procedure · Biological
Lead sponsor
North American Consortium for Histiocytosis
Other
Eligibility
Up to 18 Years
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2031
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 15, 2026, 4:00 AM EST
Enrolling by invitation Phase 3 Interventional

A Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE) (ENSEMBLE)

NCT06431893
View directory record Official record
Conditions
Homocystinuria
Interventions
Pegtibatinase
Drug
Lead sponsor
Travere Therapeutics, Inc.
Industry
Eligibility
5 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
13
States / cities
Phoenix, Arizona • New Haven, Connecticut • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 15, 2026, 4:00 AM EST
Active, not recruiting Phase 1 Interventional

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

NCT06561685
View directory record Official record
Conditions
Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, SMARCA4-Deficient Tumor
Interventions
LY4050784, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Nab paclitaxel
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
17
States / cities
Santa Monica, California • Aurora, Colorado • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 15, 2026, 4:00 AM EST
Recruiting Phase 3 Interventional

PRE-EMPT: Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis

NCT07232069
View directory record Official record
Conditions
Coronary Artery Disease Risk Factors Multiple, Coronary Artery Disease Progression, Prevention & Control, Premature Atherosclerosis
Interventions
Rosuvastatin 20 Mg Oral Tablet, Colchicine 0.5 MG Oral Tablet Once Daily, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
30 Years to 60 Years
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
23
States / cities
Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 15, 2026, 4:00 AM EST
Recruiting Phase 4 Interventional

Immune Modulation During Palynziq® Treatment in Adults (IMPALA)

NCT07477691
View directory record Official record
Conditions
Phenylketonuria
Interventions
Pegvaliase, Methotrexate
Biological · Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
12
States / cities
Los Angeles, California • Aurora, Colorado • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 15, 2026, 4:00 AM EST
Recruiting Phase 2 Interventional

RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

NCT07002034
View directory record Official record
Conditions
Adjustment Disorder
Interventions
RE104 for Injection
Drug
Lead sponsor
Reunion Neuroscience Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
33
States / cities
Birmingham, Alabama • Tucson, Arizona • San Diego, California + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 15, 2026, 4:00 AM EST
Recruiting Phase 3 Interventional

A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia

NCT07144163
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
Interventions
Atumelnant, Placebo
Drug
Lead sponsor
Crinetics Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
15
States / cities
Los Angeles, California • Aurora, Colorado • Gainesville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 15, 2026, 4:00 AM EST
Recruiting Phase 2 Interventional

A Trial to Evaluate the Safety, Tolerability and Efficacy of AIC263029 in Kidney Transplant Recipients With BKV Infection

NCT07503561
View directory record Official record
Conditions
BK Virus Infection, BKV Infection, Kidney Transplant
Interventions
AIC263029, Placebo
Drug
Lead sponsor
AiCuris Anti-infective Cures AG
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • Tampa, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 15, 2026, 4:00 AM EST
Completed Phase 2 Interventional Results available

Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer

NCT02339558
View directory record Official record
Conditions
Nasopharyngeal Nonkeratinizing Carcinoma, Recurrent Nasopharynx Carcinoma, Stage III Nasopharyngeal Carcinoma AJCC v7, Stage IV Nasopharyngeal Carcinoma AJCC v7, Stage IVA Nasopharyngeal Carcinoma AJCC v7, Stage IVB Nasopharyngeal Carcinoma AJCC v7, Stage IVC Nasopharyngeal Carcinoma AJCC v7
Interventions
Laboratory Biomarker Analysis, Nivolumab
Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
15
States / cities
Duarte, California • Los Angeles, California • Pasadena, California + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 15, 2026, 4:00 AM EST